![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
|Articles|July 1, 2001
Oncology NEWS International
- Oncology NEWS International Vol 10 No 7
- Volume 10
- Issue 7
HHS Releases Guide for Treating Women With HIV
ROCKVILLE, Md-With HIV infections rising among American women, the Department of Health and Human Services (HHS) has published The Clinical Guide for the Care of Women With HIV. The full text is available online at http://hab.hrsa.gov/womencare.htm.
Advertisement
ROCKVILLE, MdWith HIV infections rising among American women, the Department of Health and Human Services (HHS) has published The Clinical Guide for the Care of Women With HIV. The full text is available online at
Articles in this issue
about 25 years ago
NCI to Expand Its Support for Trials of STI-571about 25 years ago
Patients and Physicians Differ on Chemotherapy Expectationsabout 25 years ago
Concurrent Chemoradiotherapy Helps Preserve Larynxabout 25 years ago
FDA Issues New Safeguards for Children in Clinical Trialsabout 25 years ago
Leukemia Society Offers Patient Information on Use of STI-571Advertisement
Related to this article
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5